man_at_mouse
man_at_mouse / iStockphoto.com
1 February 2018Americas

LSIPR webinar: BSKB dissects antibody patents

When it comes to patenting antibodies, “written description seems to be the big issue these days”, according to Gerald Murphy, IP partner at law firm Birch Stewart Kolasch Birch (BSKB).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
28 September 2017   Unlike in Europe, the lack of a plausibility threshold in the US means that those applying for patents there are more likely to be granted a broader claim.
Europe
22 March 2018   Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.
Big Pharma
6 August 2020   Antibody patenting can be a minefield for IP practitioners if they lack the most up-to-date knowledge about the best way to approach a patent application.

More on this story

Americas
28 September 2017   Unlike in Europe, the lack of a plausibility threshold in the US means that those applying for patents there are more likely to be granted a broader claim.
Europe
22 March 2018   Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.
Big Pharma
6 August 2020   Antibody patenting can be a minefield for IP practitioners if they lack the most up-to-date knowledge about the best way to approach a patent application.

More on this story

Americas
28 September 2017   Unlike in Europe, the lack of a plausibility threshold in the US means that those applying for patents there are more likely to be granted a broader claim.
Europe
22 March 2018   Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s opposition procedure.
Big Pharma
6 August 2020   Antibody patenting can be a minefield for IP practitioners if they lack the most up-to-date knowledge about the best way to approach a patent application.